Profile data is unavailable for this security.
About the company
IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. Its segments include Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment offers mission-critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions segment serves biopharmaceutical customers and provides outsourced clinical research and clinical trial related services. Contract Sales & Medical Solutions segment offers health care providers (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market. Its Connected Intelligence delivers insights and solutions enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients.
- Revenue in USD (TTM)15.16bn
- Net income in USD1.42bn
- Incorporated2016
- Employees88.00k
- LocationIQVIA Holdings Inc2400 ELLIS ROADDURHAM 27703United StatesUSA
- Phone+1 (919) 998-2000
- Fax+1 (302) 636-5454
- Websitehttps://ir.iqvia.com/
Mergers & acquisitions
| Acquired company | IQV:NYQ since announced | Transaction value |
|---|---|---|
| Open Applications Consulting Ltd | 23.15% | -- |
| Bitac Map SL | 19.08% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICON PLC | 8.33bn | 714.43m | 24.92bn | 41.10k | 34.97 | 2.60 | 19.04 | 2.99 | 8.60 | 8.60 | 100.31 | 115.74 | 0.489 | -- | 3.01 | 202,722.40 | 4.19 | 3.93 | 5.00 | 4.80 | 29.75 | 28.91 | 8.57 | 7.37 | -- | 3.86 | 0.264 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Moderna Inc | 5.05bn | -5.87bn | 26.15bn | 5.60k | -- | 2.23 | -- | 5.18 | -15.37 | -15.37 | 13.21 | 30.50 | 0.2689 | 3.12 | 25.57 | 901,785.70 | -31.24 | 20.95 | -36.58 | 29.51 | 65.60 | -- | -116.18 | 32.10 | 3.92 | -- | 0.0469 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.34bn | -72.94m | 35.48bn | 2.10k | -- | -- | -- | 15.13 | -0.6285 | -0.6285 | 18.39 | -0.024 | 0.6326 | 3.31 | 158.02 | 1,116,384.00 | -1.97 | -26.56 | -2.62 | -32.77 | 87.00 | 83.66 | -3.11 | -94.26 | 2.93 | 0.6753 | 1.00 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Iqvia Holdings Inc | 15.16bn | 1.42bn | 44.59bn | 88.00k | 31.74 | 6.64 | 17.35 | 2.94 | 7.71 | 7.71 | 82.07 | 36.83 | 0.5781 | -- | 4.74 | 174,195.40 | 5.44 | 3.24 | 7.26 | 4.07 | 35.10 | 34.32 | 9.40 | 6.03 | -- | 3.27 | 0.6638 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 19.49m | 10.69% |
| Harris Associates LPas of 30 Jun 2024 | 10.67m | 5.85% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 10.32m | 5.66% |
| GIC Pte Ltd. (Investment Management)as of 13 Aug 2024 | 9.13m | 5.01% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 8.03m | 4.40% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.22m | 2.32% |
| AllianceBernstein LPas of 30 Jun 2024 | 4.02m | 2.21% |
| Canada Pension Plan Investment Boardas of 30 Jun 2024 | 3.40m | 1.87% |
| Lazard Asset Management LLCas of 30 Jun 2024 | 3.29m | 1.80% |
| Farallon Capital Management LLCas of 30 Jun 2024 | 2.92m | 1.60% |
